Get the Stockscreener App
0.70
2.34%
0.016
After Hours:
.70
Passage Bio Inc stock is traded at $0.70, with a volume of 141.44K.
It is up +2.34% in the last 24 hours and down -0.09% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
See More
Previous Close:
$0.684
Open:
$0.67
24h Volume:
141.44K
Relative Volume:
0.53
Market Cap:
$43.24M
Revenue:
-
Net Income/Loss:
$-112.38M
P/E Ratio:
-0.3415
EPS:
-2.05
Net Cash Flow:
$-83.38M
1W Performance:
+8.33%
1M Performance:
-0.09%
6M Performance:
-48.15%
1Y Performance:
+6.38%
1-Day Range:
$0.66
$0.7199
1-Week Range:
$0.601
$0.7199
52-Week Range:
$0.5751
$1.79
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Passage Bio’s CEO to Present at Prestigious Genetic Medicines Conference - MSN
Passage Bio’s CEO to Present at Prestigious Genetic Medicines Conference - MyChesCo
Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers - Yahoo Finance
Market Insights: Gatos Silver Inc (GATO)’s Notable Drop of -2.63, Closing at 15.18 - The Dwinnex
NanoMosaic Transforms Cell and Gene Therapy Analytics with Advanced Quantification and Genome Mapping Capabilities. World-Renowned Expert Dr. Guangping Gao to Join Nanomosaic Scientific Advisory Board - StreetInsider.com
CASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above Two Hundred Day Moving Average of $4.60 - Defense World
OrbiMed Advisors sells shares in Passage BIO worth over $27k - Investing.com Canada
OrbiMed Advisors sells shares in Passage BIO worth over $27k - Investing.com India
OrbiMed Advisors sells shares in Passage BIO worth over $27k - Investing.com
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference - ForexTV.com
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference - GlobeNewswire
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference - StockTitan
Mercer Global Advisors Inc. ADV Acquires 10,658 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MSN
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - Yahoo Finance
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MyChesCo
OrbiMed Advisors sells shares of Passage Bio worth over $146,000 - Investing.com
OrbiMed Advisors sells shares of Passage Bio worth over $146,000 By Investing.com - Investing.com UK
Canaccord sees Passage Bio stock potential in positive Phase 1/2 trial data - Investing.com
PASG’s 52-Week Rollercoaster: From $0.58 to $1.79 – What’s Next for Investors? - The InvestChronicle
Canaccord sees Passage Bio stock potential in positive Phase 1/2 trial data - Investing.com India
Canaccord sees Passage Bio stock potential in positive Phase 1/2 trial data - Investing.com Australia
Financial Metrics Unveiled: Passage Bio Inc (PASG)’s Key Ratios in the Spotlight - The Dwinnex
Canaccord sees Passage Bio stock potential in positive Phase 1/2 trial data - Investing.com UK
Passage Bio Reveals Promising Gene Therapy Trial Results - TipRanks
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) - StockTitan
Passage Bio to Present Positive Interim Data from Cohort 1 - GlobeNewswire
Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision - MSN
Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision - MyChesCo
Passage Bio appoints new director and grants stock options - Investing.com
Passage Bio appoints new director and grants stock options - Investing.com India
Passage Bio adds biotech veteran Tom Kassberg to board - Investing.com
Passage Bio Appoints Tom Kassberg to Board of Directors - citybiz
Passage Bio appoints Tom Kassberg to board of directors - TipRanks
Passage Bio Welcomes Tom Kassberg to Board of Directors - GlobeNewswire
Passage Bio Welcomes Tom Kassberg to Board of Directors - StockTitan
Passage Bio Appoints Thomas Kassberg to Leadership Team - TipRanks
Passage Bio projects $3.5M-$5.5M impairment costs - Investing.com
Passage Bio projects $3.5M-$5.5M impairment costs - Investing.com India
Biopharma Layoff Tracker 2024: Connect Biopharma, BioMarin and More Cut Staff - BioSpace
Passage Bio projects $3.5M-$5.5M impairment costs By Investing.com - Investing.com Canada
Passage Bio projects $3.5M-$5.5M impairment costs By Investing.com - Investing.com UK
Annovis Bio’s CEO to Present at H.C. Wainwright Global Investment Conference - MyChesCo
Passage Bio (NASDAQ:PASG) Now Covered by Analysts at Rodman & Renshaw - Defense World
Frontotemporal Dementia Market to Grow Positively at - openPR
GM1 Gangliosidosis Market to Register Incremental Growth - openPR
Passage Bio Inc Inc. (PASG) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Passage Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Passage Bio (NASDAQ:PASG) Stock Quotes, Forecast and News Summary - Benzinga
Passage Bio CEO to Present at H.C. Wainwright Global Investment Conference - MyChesCo
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):